Is serum tumor marker half-life a guide to prognosis in metastatic nonseminomatous germ cell tumors?

Anticancer Research

Volumn 17, Issue 4 B, 1997, Pages 3047-3049

  Gerl, Arthur ^a   Lamerz, Rolf ^a   Mann, Klaus ^a   Clemm, Christoph ^a   Wilmanns, Wolfgang ^a  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

Author keywords

Alpha fetoprotein (AFP); Half life analysis; Human chorionic gonadotropin (HCG); Nonseminomatous germ cell tumors prognosis; Tumor markers

Indexed keywords

ALPHA FETOPROTEIN; BLEOMYCIN; CHORIONIC GONADOTROPIN; CISPLATIN; CYCLOPHOSPHAMIDE; ETOPOSIDE; TUMOR MARKER; VINBLASTINE;

CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER SURVIVAL; CONFERENCE PAPER; HALF LIFE TIME; HUMAN; MAJOR CLINICAL STUDY; MALE; NON SEMINOMATOUS GERMINOMA; PATIENT SELECTION; PRIORITY JOURNAL; PROGNOSIS; PROTEIN BLOOD LEVEL; RETROSPECTIVE STUDY; TREATMENT OUTCOME;

ALPHA-FETOPROTEINS; CHORIONIC GONADOTROPIN; GERMINOMA; HALF-LIFE; HUMANS; NEOPLASM METASTASIS; PROGNOSIS; RETROSPECTIVE STUDIES; TUMOR MARKERS, BIOLOGICAL;

EID: 0030757774     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (9)

1. Toner GC, Geller NL, Tan C, Nisselbaum J, Bosl GJ: Serum tumor marker half-life during chemotherapy allows early prediction of complete response and survival in NSGCT. Cancer Res 50: 5904-5910, 1990.
2. Stevens MJ, Norman AR, Dearnaley DP, Horwich A: Prognostic significance of early serum tumor marker half-life in metastatic testicular teratoma. J Clin Oncol 13: 87-92, 1995.
3. Mead GM, Stenning SP, Parkinson MC, Horwich A, Fossa SD, Wilkinson PM et al: The second Medical Research Council study of prognostic factors in noseminomatous germ cell tumors. J Clin Oncol 10: 85-94, 1992.
4. Saller B, Clara R, Spöttl G, Siddle K, Mann K: Testicular cancer secretes intact human choriongonadotropin (hCG) and its free beta-subunit: evidence that hCG (+ hCG-beta) assays are the most reliable in diagnosis and follow-up. Clin Chem 36: 234-239, 1990.
5. Lamerz R, Rjosk H, Schmalhorst U, Fateh-Moghadam A: Alpha-Fetoprotein: Methodik and klinische Erfahrungen mit einem neuen Radioimmunoassay. Z Anal Chem 279: 120, 1976.
6. Kohn J: The value of apparent half-life assay of alpha-1 fetoprotein in the management of testicular teratoma. In: Carcinoembryonic Proteins (Lehmann FG, ed.). Amsterdam, The Netherlands Elsevier /North Holland Biomedical, 1979, pp. 383-386.
7. Kaplan EL, Meier P: Non-parametric estimation from incomplete observations. J Amer Stat Assoc 53: 457-481, 1958.
8. Mantel N, Haenszel W: Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst 22: 719-748, 1959.
9. Lange PH, Vogelzang NJ, Goldman A, Kennedy BJ, Fraley EE: Marker half-life analysis as a prognostic tool in testicular cancer. J Urol 128: 708-711,1982.